Lisata Therapeutics, Inc. (LSTA) stock
LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.21−0.07 (-5.47%)
Close on Nov 13, 2026Market cap $10.90MP/E –Yield –
Lisata Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Lisata Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $8.13M, down 16.8% year over year. For fiscal 2025 it was $7.95M, down 29.9% from the year before. Over ten years it grew -10.4% a year on average. The highest annual figure on record is $29.19M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.95M | -29.9% |
| FY2024 | Dec 31, 2024 | $11.33M | -11.0% |
| FY2023 | Dec 31, 2023 | $12.73M | -2.5% |
| FY2022 | Dec 31, 2022 | $13.07M | -25.7% |
| FY2021 | Dec 31, 2021 | $17.58M | +89.9% |
| FY2020 | Dec 31, 2020 | $9.25M | -14.3% |
| FY2019 | Dec 31, 2019 | $10.80M | +42.2% |
| FY2018 | Dec 31, 2018 | $7.59M | -52.1% |
| FY2017 | Dec 31, 2017 | $15.84M | -5.1% |
| FY2016 | Dec 31, 2016 | $16.70M | -30.1% |
| FY2015 | Dec 31, 2015 | $23.90M | -18.1% |
| FY2014 | Dec 31, 2014 | $29.19M | +72.6% |
| FY2013 | Dec 31, 2013 | $16.92M | +61.9% |
| FY2012 | Dec 31, 2012 | $10.45M | +35.4% |
| FY2011 | Dec 31, 2011 | $7.72M | +0.5% |
| FY2010 | Dec 31, 2010 | $7.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.21M | +165.7% |
| Q2 FY2026 | Jun 30, 2026 | $584.00K | -74.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.20M | -53.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.13M | -61.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.96M | -22.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.25M | -13.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.60M | -19.7% |
| Q4 FY2024 | Dec 31, 2024 | $2.95M | -2.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.54M | -24.8% |
| Q2 FY2024 | Jun 30, 2024 | $2.60M | -17.7% |
| Q1 FY2024 | Mar 31, 2024 | $3.24M | +2.0% |
| Q4 FY2023 | Dec 31, 2023 | $3.01M | -6.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.38M | +1.3% |
| Q2 FY2023 | Jun 30, 2023 | $3.16M | -2.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.18M | -3.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.21M | -20.6% |
| Q3 FY2022 | Sep 30, 2022 | $3.34M | -19.2% |
| Q2 FY2022 | Jun 30, 2022 | $3.23M | -25.3% |
| Q1 FY2022 | Mar 31, 2022 | $3.28M | -35.3% |
| Q4 FY2021 | Dec 31, 2021 | $4.05M | +39.2% |
| Q3 FY2021 | Sep 30, 2021 | $4.13M | +36.2% |
| Q2 FY2021 | Jun 30, 2021 | $4.33M | +138.1% |
| Q1 FY2021 | Mar 31, 2021 | $5.08M | +238.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.91M | +5.1% |
| Q3 FY2020 | Sep 30, 2020 | $3.03M | +0.8% |
| Q2 FY2020 | Jun 30, 2020 | $1.82M | -39.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.50M | -26.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.77M | +83.5% |
| Q3 FY2019 | Sep 30, 2019 | $3.00M | +76.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.99M | +40.7% |
| Q1 FY2019 | Mar 31, 2019 | $2.04M | -9.9% |
| Q4 FY2018 | Dec 31, 2018 | $1.51M | -67.6% |
| Q3 FY2018 | Sep 30, 2018 | $1.70M | -46.6% |
| Q2 FY2018 | Jun 30, 2018 | $2.12M | -50.4% |
| Q1 FY2018 | Mar 31, 2018 | $2.26M | -39.3% |
| Q4 FY2017 | Dec 31, 2017 | $4.65M | +45.2% |
| Q3 FY2017 | Sep 30, 2017 | $3.19M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.28M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.20M | – |
See a number that looks wrong?